Group items tagged

NIJ is seeking investigator-initiated proposals to conduct research that examines criminal justice tools, protocols, and policies concerning drug trafficking, markets and use, and the effects of drug legalization and decriminalization on law enforcement, applicable to State, tribal and local jurisdictions. Proposals must address one of two criminal justice activities: drug intelligence and community surveillance, or criminal investigation and prosecution. In addition, NIJ has identified three drug research priorities: Marijuana and cannabis products; Heroin and other opioids (including diverted prescription drugs); and Novel psychoactive substances (also known as synthetic drugs).

NIJ is seeking investigator-initiated proposals to conduct research that examines criminal justice tools, protocols, and policies concerning drug trafficking, markets and use, and the effects of drug legalization and decriminalization on law enforcement, applicable to State, tribal and local jurisdictions. Proposals must address one of two criminal justice activities: drug intelligence and community surveillance, or criminal investigation and prosecution. In addition, NIJ has identified three drug research priorities: Marijuana and cannabis products; Heroin and other opioids (including diverted prescription drugs); and Novel psychoactive substances (also known as synthetic drugs).

The nasal mucosa offers an effective target for inhaled drugs that either treat localized nasal conditions or quickly deliver drugs to the systemic circulation [1-3]. While nasal spray drug product designs can vary considerably between innovators, most sprays are formulated as either a homogeneous solution or a heterogeneous suspension; in the latter case, solid drug particles are dispersed within a carrier liquid [4]. Despite the many advancements in nasal drug delivery, effectively administering drugs via this route still poses many challenges. One of the main challenges relates to mucociliary motion, which tends to transport and clear drug particles from the nasal cavity after deposition, limiting the available time for drug absorption at the intended site of action [5-8].Many previous nasal spray models have considered solution formulations, where the active drug is already dissolved into a carrier liquid [9-11]

The Office of National Drug Control Policy (ONDCP), Executive Office of the President, is seeking applications from public nonprofit institutions/organizations (includes institutions of higher education and hospitals) to perform research and analysis of data to inform drug policy. This project seeks to further refine a methodology for obtaining drug early warning indicators from expanded testing of urine samples that were previously collected and tested as part of an existing drug test protocol. This method was initially developed using local criminal justice populations - including persons in pre-trial or lock-up, parolees or probationers, and drug court participants. In addition, this method was also tested in two trauma units, with promising results. This project will use similar methodology in criminal justice, health care, and other venues, to include opioid treatment admissions, trauma units or emergency departments, and criminal justice programs such as parole or probation, where biological samples are often collected from clients.

To that end, grants of up to $5 million will be awarded in support of research on innovative pharmacologic interventions for Alzheimer's disease and related dementias, including clinical trials, regulatory studies for novel drugs (small molecules and biologics, including antibodies, peptides, gene therapies), repurposed drugs (existing drugs that are approved for other diseases and conditions), repositioned drugs (existing drugs that have entered clinical trials for other indications and have not yet been approved), and natural products.

The Office of National Drug Control Policy (ONDCP), Executive Office of the President, is seeking applications from public nonprofit institutions/organizations (includes institutions of higher education and hospitals) to perform research and analysis of data to inform drug policy. This project seeks to further refine a methodology for obtaining drug early warning indicators from expanded testing of urine samples that were previously collected and tested as part of an existing drug test protocol. This method was initially developed using local criminal justice populations - including persons in pre-trial or lock-up, parolees or probationers, and drug court participants. 

The Alzheimer's Drug Discovery Foundation has issued a Request for Proposals for its Preclinical Drug Discovery program. Through the program, grants of up to $600,000 over two years will be awarded to promising preclinical drug discovery programs relevant to Alzheimer's disease, related dementias, and cognitive aging. Preclinical research funding priorities include high throughput screening, medicinal chemistry hit-to-lead development and optimization, in vitro and in vivo efficacy studies, ADME, toxicology, pharma-cokinetics and pharma-co-dynamics, and in vivo proof-of-concept with lead compounds and biologics. Program areas of particular interest include new chemical compounds for Alzheimer's disease, preclinical proof-of-concept, and re-purposing. With regards to potential drug targets, ADDF is interested in novel targets that include but are not limited to neuro-inflammation, protein degradation/autophagy, growth factor signaling, synaptic function/morphology, calcium regulation, energy utilization/mitochondria function, insulin sensitivity, epigenetics, ApoE function and cholesterol metabolism, vascular injury and the blood-brain barrier interface, cognitive enhancers, myelin changes, ischemia and oxidative stress, and tau-related toxicities. To be eligible, applicants must be academic investigators seeking to create and support innovative translational programs in academic medical centers and universities; biotechnology companies with programs dedicated to Alzheimer's disease translational development; and new biotechnology company spinouts or existing biotechnology companies that demonstrate a clear need for nonprofit funding. Funding is provided through program-related investments (PRIs) that require a return on investment based on scientific and/or business milestones.

Bioequivalence studies that compare a reference formulation to an investigational formulation are typically conducted in healthy adult volunteers and occasionally are conducted in patients. Some populations have unique physical, biological, and physiological considerations that are not reflected by healthy volunteers or by the typical patient for whom a drug is indicated. Physicians have expressed concerns about generic drug substitution (especially for narrow therapeutic index drugs) in special patient populations whose experience with a drug may not be represented by those in whom bioequivalence studies are conducted. For instance, for products that do not have age-appropriate formulations (e.g., formulations do not differ by age of patient), the use of generic products under "off-label" practice patterns in special populations such as crushing or dissolving tablets in liquid for pediatric patients may influence their equivalence to brand name products. Special populations include, but are not limited to, pediatric patients, elderly patients who take multiple medications, women (particularly those who are pregnant), racial/ethnic minorities, and/or individuals with impaired kidney or liver function.

The PCC has supported world-class research since 2009, spending more than $8.0 M to support novel science. Research and grant-making are the foundation of the PCC and are the focus of everyday business activity. PCC-supported research contributes to a movement in addressing doping's root causes and ultimately decreasing the use of performance-enhancing drugs by all participants in all sports at all levels of play. With an emphasis on original work that focuses on improving existing analytical methods for detecting particular drugs, developing new analytical methods to test for substances not currently detectable, and discovering cost-effective approaches for testing widely abused substances across all levels of sport, the following areas of investigation reflect the PCC's current research priorities: - Developing methods of cost-effective testing to detect and deter the use of banned and illegal substances. - Developing testing protocols to detect designer substances used for doping purposes. - Improving existing analytical methods to detect particular drugs, ex. GH, IGF-1, EPO, hCG. - Developing analytical methods to detect performance enhancing drugs not currently detectable. - Longitudinal urinary excretion patterns, metabolism and dose-concentration. - Critical reviews to support interpretation of laboratory data. - Alternative specimens, (ex. oral fluid, dried blood/plasma spots) for testing.

NineSigma, representing a Japanese leading pharmaceutical company, seeks drug discovery projects which make use of any of the following drug discovery underlying technologies and which are in a hit discovery stage. It is preferable that the research has already started; however, proposals are welcome also from an organization with plans to start a specific project in the future. The client aims to build a drug discovery platform, which is globally competitive, through collaboration with partners. The client can provide opportunities, depending on the R&D stage and the business plan of partners, and hopes not only to foster joint research and development, but also to maximize outcome creation by licensing, support with budget, etc. to support improvement of underlying technology.

The PCC has supported world-class research since 2008, spending more than $18.0 M to support novel science around the world. Research and grant-making are the foundation of the PCC and are the focus of everyday business activity. PCC-supported research contributes to a movement in addressing doping's root causes and ultimately decreasing the use of performance-enhancing drugs by all participants in all sports at all levels of play. Grant Cycle Deadlines: Pre-Applications are due March 1st, July 1st, and November 1st of each year. Applicants invited to submit full applications must do so by April 1st, August 1st, or December 1st, depending on the cycle (30 days after the pre-application due date). With an emphasis on original work that focuses on improving existing analytical methods for detecting particular drugs, developing new analytical methods to test for substances not currently detectable, and discovering cost-effective approaches for testing widely abused substances across all levels of sport, the following areas of investigation reflect the PCC's current research priorities: Developing methods of cost-effective testing to detect and deter the use of banned and illegal substances. Developing testing protocols to detect designer substances used for doping purposes. Improving existing analytical methods to detect particular drugs, ex. GH, IGF-1, EPO, hCG. Developing analytical methods to detect performance enhancing drugs not currently detectable. Longitudinal urinary excretion patterns, metabolism and dose-concentration. Critical reviews to support interpretation of laboratory data. Alternative specimens, (ex. oral fluid, dried blood/plasma spots) for testing. There is no maximum amount for PCC funding, though the average funding amount is $225,000. To date, over 80 projects have been funded in over 14 countries world-wide. Approximately 33% of applicants are awarded PCC funding.

This Funding Opportunity Announcement (FOA) will support innovative research projects that are focused on image-guided drug delivery (IGDD), including real-time image guidance, monitoring, quantitative in vivo characterizations and validation of delivery and response. It will support research in development of integrated imaging-based systems for delivery of drugs or biologics in cancer and other diseases, quantitative imaging assays of drug delivery, and early intervention.

To continue making safe and effective topical semisolid drug products available to the American public, it is essential that FDA's regulatory science, as well as best practices in the pharmaceutical industry, are informed by the most current understanding of the product quality attributes that are potentially critical to the therapeutic performance of topical semisolid dosage forms. The scope of this project is to characterize all measurable physical/chemical qualities of different dosage forms of semisolid topical drug products, identify appropriate methodologies for measuring each of these quality attributes, characterize formulation and manufacturing parameters that alter the arrangement of matter in the dosage form as measured by specific quality attributes, and utilize in vitro and/or in vivo measures of product performance to correlate variations in critical quality attributes with a failure mode for a drug product.  

Currently, the drugs are designed in such a way that the active pharmaceutical ingredient (API) is immediately released in the stomach and absorbed in the bloodstream, rapidly relieving the patient from his/her pain (left-hand side). In case multiple doses are taken all at once, a (potentially toxic) supratherapeutic amount of API immediately gets into the user's bloodstream (center). This amount is illicitly used to induce euphoria and could be potentially toxic. Grünenthal's intention is to design a drug formulation that guarantees the API's release profile in case of proper therapeutical usage. However, in case multiple drug units are taken, the release of API, that is available for absorption (right-hand side), will be limited or, at least, decreased to avoid overdosing.

The purpose of this Funding Opportunity Announcement (FOA) is to build upon the work that has begun under previous FOA RFA-TR-17-007 NCATS Pilot Program for Collaborative Drug Discovery Research Using Bioprinted Skin Tissue and utilize physiologically relevant and validated 3-D biofabricated skin disease tissue models in multi-well drug screening platforms. The FOA will support intramural- extramural collaborations to implement the use of 3-D biofabricated skin tissue models and provide evidence of success for 3-D drug screening platforms.

The purpose of this funding opportunity announcement (FOA) is to support research to continue the development of drug development tools that have an accepted Letter of Intent within CDER's Drug Development Tool Qualification Program.

The illicit sale of fentanyl, fentanyl analogues, and other synthetic drugs is incredibly profitable, and their high potency in small quantities presents a low risk to traffickers. To respond to this challenge, the U.S. government's understanding of the production, transit, and sale of these drugs and their precursor chemicals must continually increase. We will support a data analytics provider that can produce reliable information to inform our future capacity building programming efforts to combat transnational organized crime. The combination of technology and investigative research on transnational criminal organizations has various potential applications, such as building partner capacity by giving countries leads on various transnational criminal networks, identifying target cells before problems infiltrate neighboring areas, using network overviews for strategy information, and providing training on a limited basis.

The National Institute on Drug Abuse (NIDA) intends to solicit proposals from offerors having the capability to perform the following tasks: (1) cultivate and harvest, process, analyze, store, and distribute cannabis (marijuana) for research, (2) extract cannabis to produce pure and standardized (current Good Manufacturing Practices (cGMP)-grade) cannabis extracts containing varying concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), (3) isolate cGMP and research grade THC, CBD, and other cannabinoids, (4) periodically analyze cannabis extracts, and isolated cannabinoids for authenticity, purity and stability, (5) develop new methods for growing cannabis plants containing high THC, low CBD; high CBD, low THC; and equal strength of CBD and THC, (6) manufacture, analyze, determine stability, store, and supply marijuana cigarettes, and (7) supply cannabis, cannabis extract, other phyto-cannabinoids, and marijuana cigarettes to research investigators and/or to the NIDA Drug Supply program upon NIDA authorization.

The objective of this Funding Opportunity Announcement (FOA) is to support the development of new and innovative multipurpose prevention technologies (MPT) with rheological/biophysical properties and product user perceptions compatible with current long-acting reversible contraceptive (LARC) strategies (look, feel, effectiveness, safety and duration of action) for the dual purpose of preventing pregnancy and HIV infection in women. MPTs proposed for development must be dual indication and prevent pregnancy and HIV infection and have drug delivery systems (DDS) capable with sustained/extended release of both drugs. MPTs proposed for development must use a licensed contraceptive. This FOA requires an industry partner, milestones linked to Go/No Go decisions and year 5 funding requires submission of a pre-IND application to the FDA.

This Funding Opportunity Announcement (FOA) encourages grant applications from institutions or organizations that propose multidisciplinary, investigator-initiated basic translational and clinical research in developmental pharmacodynamics This FOA seek grant applications that propose studies to increase and establish data on developmental pharmacodynamics in the pediatric age groups and allows the determination of pharmacokinetic-pharmacodynamic relationship of drugs used in this population.

This Funding Opportunity Announcement (FOA) supports the optimization of potential therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene and cell therapies) for disorders identified under the NINDS mission. This track supports the further characterization and optimization of therapeutic lead(s) that showed promise as a potential therapeutic agent as evidenced by convincing animal proof-of-concept studies. Therefore, at the end of this funding period, successful projects will have delivered and optimized therapeutic candidate with demonstrated bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and should be eligible for entry into the CREATE Bio Development track. The CREATE Bio Development track is a later stage program focused on the development of optimized therapeutic candidates through Investigational New Drug (IND)-enabling studies and submission of an IND package to the Food and Drug Administration (FDA). Also Listed under (U44)